The new patent would be the final step that a big pharma wants to see. After all, there is no protection until a patent application is reviewed and approved. And, an application is no guarantee one will be approved. It is only temporary, interim, protection of IP.

There could be more than one interested party, unless the one party is the one remaining who offered an unmatched deal. This makes the overseas location even more interesting.